Evinacumab
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Homozygous Familial Hypercholesterolemia
Conditions
Homozygous Familial Hypercholesterolemia
Trial Timeline
Jun 29, 2020 → May 30, 2023
NCT ID
NCT04233918About Evinacumab
Evinacumab is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Homozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04233918. Target conditions include Homozygous Familial Hypercholesterolemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06500598 | Pre-clinical | Completed |
| NCT04863014 | Phase 2 | Terminated |
| NCT04233918 | Phase 3 | Completed |
| NCT03409744 | Phase 3 | Completed |
Competing Products
20 competing products in Homozygous Familial Hypercholesterolemia